From 60b7a0269c3308e52cbe627e62b9593b846ea1f0 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Sun, 10 May 2026 04:34:25 +0000 Subject: [PATCH] =?UTF-8?q?source:=202026-02-17-compass-pathways-comp006-p?= =?UTF-8?q?silocybin-phase3-trd-second.md=20=E2=86=92=20null-result?= MIME-Version: 1.0 Content-Type: text/plain; charset=UTF-8 Content-Transfer-Encoding: 8bit Pentagon-Agent: Epimetheus --- ...17-compass-pathways-comp006-psilocybin-phase3-trd-second.md | 3 ++- 1 file changed, 2 insertions(+), 1 deletion(-) rename inbox/{queue => null-result}/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md (98%) diff --git a/inbox/queue/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md b/inbox/null-result/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md similarity index 98% rename from inbox/queue/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md rename to inbox/null-result/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md index edd359659..b0cc28ba8 100644 --- a/inbox/queue/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md +++ b/inbox/null-result/2026-02-17-compass-pathways-comp006-psilocybin-phase3-trd-second.md @@ -7,10 +7,11 @@ date: 2026-02-17 domain: health secondary_domains: [] format: press-release -status: unprocessed +status: null-result priority: high tags: [psilocybin, treatment-resistant-depression, Phase-3, clinical-trial, mental-health, psychedelic-therapy, FDA, NDA, Compass-Pathways] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content